Co-development and Distribution Agreement on treatment for pancreatic exocrine insufficiency (SA-001) in Japan concluded
Solvay Seiyaku K. K.
Eisai Co., Ltd.
Solvay Pharmaceuticals Marketing & Licensing AG (Basel, Switzerland, President: Sjirk Kok), an affiliate of Solvay Pharmaceuticals (Brussels, Belgium, President: Werner Cautreels), and Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) concluded a license agreement on Solvay Pharmaceuticals' treatment for pancreatic exocrine insufficiency (SA-001) in Japan today. With this agreement, SA-001's co-development will be conducted by Solvay Seiyaku K. K. (Japanese entity of Solvay Pharmaceuticals, Head Office: Tokyo, President: Koji Ohiwa) and Eisai, and distribution will be conducted exclusively by Eisai. Solvay Seiyaku retains co-promotion rights with Eisai.
SA-001 is a high potent enteric enzyme that is a highly purified and formulated natural pancreatin with a proprietary technology. It is sold as Creon/ Kreon in 63 countries outside Japan including the United States, the United Kingdom, Germany, and France, and used in the treatment of maldigestion due to pancreatic exocrine insufficiency associated for example with cystic fibrosis, chronic pancreatitis, pancreatic or gastric resection.
Development in Japan is currently in preparation for a Phase III study.
Solvay Seiyaku is a Japanese entity of Solvay Pharmaceuticals, which is a pharmaceutical sector of the chemical and pharmaceutical global company, Solvay Group. It is a development-driven pharmaceutical company that seeks to fulfill carefully selected, unmet needs in the therapeutic areas of neuroscience, cardio-metabolic, and gastroenterology.
Eisai will increase its product line in the gastrointestinal area with this new agreement and, together with Solvay Seiyaku, contribute to increasing the benefits that health care provides as well as fulfilling the desires of patients and their families.